Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CD19.t-haNK
i
Other names:
CD19.t-haNK
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
ImmunityBio
Drug class:
CD19 inhibitor
Related drugs:
‹
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CMG1A46 (0)
CNTY-101 (0)
Imtox19/Imtox22 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
›
Associations
News
Trials
Filter by
Latest
6ms
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
6 months ago
Enrollment open • Combination therapy
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
8ms
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, ImmunityBio, Inc.
8 months ago
New P1 trial • Combination therapy
|
Rituxan (rituximab) • CD19.t-haNK
10ms
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2026
10 months ago
Trial completion date • Trial primary completion date • Combination therapy
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
over1year
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Apr 2023 --> Sep 2023
over 1 year ago
Trial initiation date • Combination therapy
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
over1year
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc. | Initiation date: Nov 2022 --> Mar 2023
over 1 year ago
Trial initiation date • Combination therapy
|
CD19 (CD19 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
almost2years
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ImmunityBio, Inc.
almost 2 years ago
New P1 trial • Combination therapy
|
CD19 (CD19 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • Anktiva (nogapendekin alfa inbakicept-pmln) • CD19.t-haNK
over2years
CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. (PubMed, Cytotherapy)
Expression of CCR7 receptor by off-the-shelf t-haNK cells improves their homing toward lymph node chemokines both in vitro and in vivo, resulting in superior tumor control.
over 2 years ago
Preclinical • Journal • IO biomarker
|
CD19 (CD19 Molecule) • CCL19 (C-C Motif Chemokine Ligand 19) • CCR7 (Chemokine (C-C motif) receptor 7) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
|
CD19 expression • CCR7 expresion
|
CD19.t-haNK
over3years
QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
P1, N=0, Withdrawn, ImmunityBio, Inc. | N=18 --> 0 | Not yet recruiting --> Withdrawn
over 3 years ago
Clinical • Enrollment change • Trial withdrawal
|
CD19 (CD19 Molecule)
|
CD19 expression
|
CD19.t-haNK
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login